Opus Genetics IRD Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -359.1%-87.2pp | -271.9%+173pp | -445.4%-24.7pp | -420.7%+50.3pp | -471%+93.7pp | |
| Net margin | -892.4%-543pp | -349.3%+117pp | -466.1%-88.2pp | -377.9%+51.5pp | -429.4%+94.0pp | |
| EBITDA margin | -358.7%-87.2pp | -271.5%+174pp | -445.1%-24.6pp | -420.4%+50.4pp | -470.8%+93.8pp | |
| Returns | ||||||
| Return on assets | -186%-72.2pp | -113.9%+64.4pp | -178.3%-38.7pp | -139.6%-22.4pp | -117.2%+9.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×-0.1× | 0.3×-0.1× | 0.4×0.0× | 0.4×+0.1× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 7.1×+0.7× | 6.4×+5.2× | 1.2×-0.7× | 1.9×-0.1× | 2×-1.3× | |
| Quick ratio | 7.1×+0.7× | 6.4×+5.2× | 1.2×-0.7× | 1.9×-0.1× | 2×-1.3× | |
| Cash ratio | 6.4×+0.6× | 5.8×+4.7× | 1.1×-0.5× | 1.6×-0.1× | 1.7×-1.0× | |
| Leverage | ||||||
| Debt-to-assets | 0×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | -$0.53-314% | $0.25+192% | $0.08-69.4% | $0.28+84.2% | $0.15-40.5% | |
| Valuation | ||||||
| Market capitalization | $307.14M+442% | $138.62M+40.2% | $98.85M— | —— | —— | |
| Enterprise value | $248.38M— | —— | —— | —— | —— | |
| Price / sales | 25.6×+21.5× | 9.8×+3.0× | 6.8×— | —— | —— | |
| EV / sales | 20.7×— | —— | —— | —— | —— | |
| Earnings yield | -34.8%+68.6pp | -35.8%+33.2pp | -69%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Opus Genetics's ratios come from?
- Every ratio is computed from Opus Genetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
